398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours

Published 2008 View Full Article

Authors

Keywords

Journal

EJC SUPPLEMENTS

Volume 6, Issue 12, Pages 125

Publisher

Elsevier BV

Online

2008-10-22

DOI

10.1016/s1359-6349(08)72332-2

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

EJC SUPPLEMENTS

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Become a Peeref-certified reviewer